MY187564A - Treatment of dementia - Google Patents
Treatment of dementiaInfo
- Publication number
- MY187564A MY187564A MYPI2019001119A MYPI2019001119A MY187564A MY 187564 A MY187564 A MY 187564A MY PI2019001119 A MYPI2019001119 A MY PI2019001119A MY PI2019001119 A MYPI2019001119 A MY PI2019001119A MY 187564 A MY187564 A MY 187564A
- Authority
- MY
- Malaysia
- Prior art keywords
- compound
- treatment
- dementia
- methylthioninium
- memantine
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 3
- 206010012289 Dementia Diseases 0.000 title 1
- 102000012440 Acetylcholinesterase Human genes 0.000 abstract 1
- 108010022752 Acetylcholinesterase Proteins 0.000 abstract 1
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- 229940022698 acetylcholinesterase Drugs 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 abstract 1
- 229960004640 memantine Drugs 0.000 abstract 1
- -1 methylthioninium compound Chemical class 0.000 abstract 1
- 230000000946 synaptic effect Effects 0.000 abstract 1
- 230000005062 synaptic transmission Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Valve Device For Special Equipments (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1614834.8A GB201614834D0 (en) | 2016-09-01 | 2016-09-01 | Treatment of dementia |
| PCT/EP2017/071437 WO2018041739A1 (en) | 2016-09-01 | 2017-08-25 | Treatment of dementia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY187564A true MY187564A (en) | 2021-09-30 |
Family
ID=57139937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2019001119A MY187564A (en) | 2016-09-01 | 2017-08-25 | Treatment of dementia |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10842796B2 (OSRAM) |
| EP (1) | EP3506904B1 (OSRAM) |
| JP (1) | JP7066679B2 (OSRAM) |
| KR (1) | KR102559354B1 (OSRAM) |
| CN (1) | CN109890391B (OSRAM) |
| AU (1) | AU2017318333B2 (OSRAM) |
| CA (1) | CA3034625A1 (OSRAM) |
| DK (1) | DK3506904T3 (OSRAM) |
| ES (1) | ES2847929T3 (OSRAM) |
| GB (1) | GB201614834D0 (OSRAM) |
| HR (1) | HRP20210162T1 (OSRAM) |
| MX (1) | MX384442B (OSRAM) |
| MY (1) | MY187564A (OSRAM) |
| PL (1) | PL3506904T3 (OSRAM) |
| PT (1) | PT3506904T (OSRAM) |
| SG (1) | SG11201901125TA (OSRAM) |
| SI (1) | SI3506904T1 (OSRAM) |
| WO (1) | WO2018041739A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY143757A (en) | 2006-03-29 | 2011-07-15 | Wista Lab Ltd | 3,7-diamond-10h-phenothiazine salts and their use |
| AU2007274057B2 (en) | 2006-07-11 | 2012-12-13 | TauRx Therapeutics Management Ltd | Methods of synthesis and/or purification of diaminophenothiazinium compounds |
| EP3487505B1 (en) | 2016-07-25 | 2023-05-03 | WisTa Laboratories Ltd. | Administration and dosage of diaminophenothiazines |
| EP4364801B1 (en) * | 2018-07-26 | 2025-11-12 | TauRx Therapeutics Management Ltd. | Optimised dosage of diaminophenothiazines in populations |
| US20210193322A1 (en) | 2018-09-05 | 2021-06-24 | Genting Taurx Diagnostic Centre Sdn Bhd | Network methods for neurodegenerative diseases |
| GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB201909454D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
| CN115916211A (zh) * | 2020-05-05 | 2023-04-04 | 维斯塔实验室有限公司 | 用于治疗低氧血症的甲基硫堇鎓化合物 |
| GB202006659D0 (en) * | 2020-05-05 | 2020-06-17 | Wista Lab Ltd | Therapeutic treatments |
| WO2023232764A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds |
| US20240115579A1 (en) * | 2022-09-22 | 2024-04-11 | Galenicum Health S.L.U. | Pharmaceutical compositions and manufacturing methods thereof |
| EP4342451A1 (en) * | 2022-09-22 | 2024-03-27 | Galenicum Health SLU | Pharmaceutical compositions and manufacturing methods thereof |
| WO2024178120A2 (en) * | 2023-02-21 | 2024-08-29 | Prosetta Biosciences, Inc. | Phenothiazinyl compounds and uses |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| AU2003227516B2 (en) * | 2002-05-31 | 2008-03-20 | H. Lundbeck A/S | A combination of an NMDA-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease |
| SI2322517T1 (sl) | 2004-09-23 | 2019-06-28 | Wista Laboratories Ltd. | Postopki za kemijsko sintezo in čiščenje diaminofenotiazinijevih spojin, vključno metiltioninijevega klorida (MTC) |
| DK2001556T3 (da) * | 2006-03-29 | 2014-11-10 | Wista Lab Ltd | Thioninium-forbindelser og anvendelse deraf |
| MY143757A (en) | 2006-03-29 | 2011-07-15 | Wista Lab Ltd | 3,7-diamond-10h-phenothiazine salts and their use |
| FR2899107B1 (fr) * | 2006-03-30 | 2008-06-13 | Neurokin Entpr Unipersonnelle | Utilisation de la (s)-roscovitine pour la fabrication d'un medicament |
| AU2007274057B2 (en) | 2006-07-11 | 2012-12-13 | TauRx Therapeutics Management Ltd | Methods of synthesis and/or purification of diaminophenothiazinium compounds |
| FR2903696B1 (fr) | 2006-07-12 | 2011-02-11 | Provence Technologies | Procede de purification de composes diaminophenothiazium |
| US9034890B2 (en) * | 2006-11-15 | 2015-05-19 | Steven A. Rich | Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases |
| CA2690746C (en) * | 2007-06-19 | 2018-01-02 | Wista Laboratories Ltd | Phenothizine compounds for treating mild cognitive impairment |
| SI2954932T1 (sl) | 2007-10-03 | 2019-01-31 | Wista Laboratories Ltd. | Terapevtska uporaba diaminofenotiazinov |
| PT2480540T (pt) | 2009-09-24 | 2018-02-16 | Wista Lab Ltd | Pentahidrato de cloreto de metiltionínio e respetivas preparação e utilização farmacêutica |
| KR20180094126A (ko) | 2009-09-24 | 2018-08-22 | 위스타 레보레이토리스 리미티드 | 결정질 메틸티오니늄 클로라이드（메틸렌 블루） 수화물 |
| SG192666A1 (en) * | 2011-02-11 | 2013-09-30 | Wista Lab Ltd | Phenothiazine diaminium salts and their use |
| CN102936244B (zh) * | 2012-12-04 | 2015-02-04 | 合肥工业大学 | 一种他克林-吩噻嗪异二联体类化合物及其制备方法 |
-
2016
- 2016-09-01 GB GBGB1614834.8A patent/GB201614834D0/en not_active Ceased
-
2017
- 2017-08-25 EP EP17761842.8A patent/EP3506904B1/en active Active
- 2017-08-25 ES ES17761842T patent/ES2847929T3/es active Active
- 2017-08-25 SG SG11201901125TA patent/SG11201901125TA/en unknown
- 2017-08-25 SI SI201730630T patent/SI3506904T1/sl unknown
- 2017-08-25 KR KR1020197009175A patent/KR102559354B1/ko active Active
- 2017-08-25 WO PCT/EP2017/071437 patent/WO2018041739A1/en not_active Ceased
- 2017-08-25 MY MYPI2019001119A patent/MY187564A/en unknown
- 2017-08-25 AU AU2017318333A patent/AU2017318333B2/en active Active
- 2017-08-25 MX MX2019002429A patent/MX384442B/es unknown
- 2017-08-25 CN CN201780067154.4A patent/CN109890391B/zh active Active
- 2017-08-25 JP JP2019511720A patent/JP7066679B2/ja active Active
- 2017-08-25 CA CA3034625A patent/CA3034625A1/en active Pending
- 2017-08-25 PL PL17761842T patent/PL3506904T3/pl unknown
- 2017-08-25 DK DK17761842.8T patent/DK3506904T3/da active
- 2017-08-25 HR HRP20210162TT patent/HRP20210162T1/hr unknown
- 2017-08-25 PT PT177618428T patent/PT3506904T/pt unknown
- 2017-08-25 US US16/329,611 patent/US10842796B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018041739A1 (en) | 2018-03-08 |
| JP2019526571A (ja) | 2019-09-19 |
| PL3506904T3 (pl) | 2021-07-26 |
| AU2017318333B2 (en) | 2023-05-11 |
| EP3506904B1 (en) | 2020-12-09 |
| CA3034625A1 (en) | 2018-03-08 |
| EP3506904A1 (en) | 2019-07-10 |
| KR102559354B1 (ko) | 2023-07-26 |
| MX2019002429A (es) | 2019-07-08 |
| US20190192530A1 (en) | 2019-06-27 |
| GB201614834D0 (en) | 2016-10-19 |
| ES2847929T3 (es) | 2021-08-04 |
| CN109890391B (zh) | 2023-01-31 |
| MX384442B (es) | 2025-03-14 |
| SI3506904T1 (sl) | 2021-03-31 |
| KR20190045273A (ko) | 2019-05-02 |
| US10842796B2 (en) | 2020-11-24 |
| AU2017318333A1 (en) | 2019-04-18 |
| SG11201901125TA (en) | 2019-03-28 |
| DK3506904T3 (da) | 2021-01-04 |
| PT3506904T (pt) | 2021-02-02 |
| CN109890391A (zh) | 2019-06-14 |
| JP7066679B2 (ja) | 2022-05-13 |
| HRP20210162T1 (hr) | 2021-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY187564A (en) | Treatment of dementia | |
| EP3268086A4 (en) | Lsd for the treatment of alzheimer's disease | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| PH12017500621A1 (en) | Triazolopyrazinones as pde1 inhibitors | |
| MX2018008105A (es) | Compuestos inhibidores de metaloenzima. | |
| PH12017501990B1 (en) | Imidazopyrazinones as pde1 inhibitors | |
| WO2019173795A3 (en) | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease | |
| BR112016018062A8 (pt) | compostos terapêuticos, composição farmacêutica e usos | |
| MX378940B (es) | Trastornos neurodegenerativos. | |
| ZA201805407B (en) | Composition for the prevention or treatment of neurodegenerative diseases. | |
| MX2017016114A (es) | Metodos para tratar o prevenir una proteopatia. | |
| PH12016501938A1 (en) | Halogenated quinazolin-thf-amines as pde1 inhibitors | |
| PH12016501495A1 (en) | Hexahydrofuropyrroles as pde1 inhibitors | |
| WO2015109318A3 (en) | Therapeutic methods | |
| WO2015165980A3 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| WO2016182812A8 (en) | Activation of neuronal store-operated calcium entry pathway for the treatment of alzheimer's disease | |
| SMT202100138T1 (it) | Derivato di 5-metil-6-fenil-4,5-diidr0-2h-piridazin-3-0ne per il trattamento di tumori cerebrali | |
| EP3589272A4 (en) | METHODS FOR PREVENTING PROPHYLAXIS, SLOWING EVOLUTION OR TREATING ALZHEIMER'S DISEASE | |
| EP3244897A4 (en) | Methods for treating alzheimer's disease | |
| DK3148588T3 (en) | N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease | |
| BR112017018119A2 (pt) | processo para a preparação de triazóis | |
| HK1239538A1 (en) | Drug combinations to treat multiple myeloma | |
| GB201614863D0 (en) | Alzheimer's disease | |
| BR112017003430A2 (pt) | comprimido revestido com filme para o tratamento de dor aguda | |
| TH166563A (th) | ควินาโซลิน-thf-เอมีนที่ถูกฮาโลจิเนตที่เป็นตัวยับยั้ง pde1 |